TY - JOUR
T1 - Bendamustine and rituximab, as first line treatment, in intermediate, high risk splenic marginal zone lymphomas of elderly patients
AU - Castelli, Roberto
AU - Gidaro, Antonio
AU - Deliliers, Giorgio Lambertenghi
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin's lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of >10 years. The typical clinical features of SMZL include splenomegaly. Treatment should be patient-tailored and can range from a 'watchful waiting' approach for asymptomatic patients without cytopenias to surgery, localized radiation therapy or immuno/chemotherapies. Recently, the combination of rituximab and Bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in SMZL. Aim of the study: The purpose of this retrospective study was to report our experience on the efficacy of R-Benda as first line treatment in 23 consecutive elderly SMZL patients. Results: All patients had a complete resolution of splenomegaly along with restoration of their blood counts. Nineteen patients (83%) achieved a complete response (CR) to therapy; three patients (13%) achieved a partial response (PR).Ten patients (43%) obtained molecular remission. Toxicities were mild and mainly haematological and result in dose reductions for fourteen patients. Conclusions: Our data suggest a high activity and good tolerance of R-Benda, despite dose reduction due to potential toxicity.
AB - Background: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin's lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of >10 years. The typical clinical features of SMZL include splenomegaly. Treatment should be patient-tailored and can range from a 'watchful waiting' approach for asymptomatic patients without cytopenias to surgery, localized radiation therapy or immuno/chemotherapies. Recently, the combination of rituximab and Bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in SMZL. Aim of the study: The purpose of this retrospective study was to report our experience on the efficacy of R-Benda as first line treatment in 23 consecutive elderly SMZL patients. Results: All patients had a complete resolution of splenomegaly along with restoration of their blood counts. Nineteen patients (83%) achieved a complete response (CR) to therapy; three patients (13%) achieved a partial response (PR).Ten patients (43%) obtained molecular remission. Toxicities were mild and mainly haematological and result in dose reductions for fourteen patients. Conclusions: Our data suggest a high activity and good tolerance of R-Benda, despite dose reduction due to potential toxicity.
UR - http://www.scopus.com/inward/record.url?scp=84976510276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976510276&partnerID=8YFLogxK
U2 - 10.4084/mjhid.2016.030
DO - 10.4084/mjhid.2016.030
M3 - Article
AN - SCOPUS:84976510276
VL - 8
JO - Mediterranean Journal of Hematology and Infectious Diseases
JF - Mediterranean Journal of Hematology and Infectious Diseases
SN - 2035-3006
IS - 1
M1 - e2016030
ER -